Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
ASTELLAS US LLC
Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company
May 26, 2026
Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026
May 18, 2026
IZERVAY® (avacincaptad pegol intravitreal solution) Demonstrated Increased Probability of Maintaining Driving Eligibility in Geographic Atrophy Patients
May 12, 2026
Astellas to Highlight New Findings for Geographic Atrophy at ARVO 2026 Annual Meeting
April 30, 2026
U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
April 20, 2026
Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
December 11, 2025
Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
December 6, 2025